Message from the Chair

Stephanie Fitch, P&HT Chair

Well, it’s that time of year again. A new picture on the front cover of CapLits, a huge sigh of relief from the Program Planners for the Annual Meeting and a gasp of realisation from the Planners of the next Annual Meeting as they realise that their first deadline is only three weeks away!

But before we start to think about next year in earnest, just a word or two about the meeting in New York. First of all, a huge, stupendous vote of thanks to Karen Mirabile and her team. Together they pulled together a wonderful program and we were, without doubt, the envy of many other Divisions who openly asked if they could use some of Karen’s ideas in their own programs next year.

In addition, to those of you who were able to attend this year, another big thank-you for making all of our Division sessions a huge success (for the most part, our sessions were ‘standing-room only’) and to those of you who were not able to make it, we hope that this issue of CapLits will capture, at least in part, some of the valuable information that was shared in New York. Copies of the slides used in the presentations have been posted to the Division website and summaries are included in this newsletter.

Of course, the meeting in New York, was not only about the sessions, we also held our Annual Business Meeting where outgo-
STN® provides you with the pharmaceutical information you need to:

A World of Pharmaceutical Information

- support your current product line
- innovate the drugs and medical devices of the future
- protect your companies’ substantial R&D investments

Explore what STN has to offer at: http://www.cas.org/PHARM/pharm.html

and see how STN can help you:

- discover new chemical entities
- watch for patents
- research pharmacology and toxicology
- search for pharmaceutics
- find drug names
- monitor worldwide drug developments

With STN’s large collection of pharmaceutical databases and elegant search features, there’s no reason to go elsewhere.

Phone: 800-753-4227, North America, 614-447-3731, Worldwide
Fax: 614-447-3751
E-mail: help@cas.org

CAS®
A division of the American Chemical Society
and know that she will do a great job in her new role and Larry, although fairly new to our Division, has a great deal of experience in working with ‘big’ SLA and he has already proved to be a very valuable advisor, so I am very happy to be working with both Karen and Larry.

For a complete list of the 2003-2004 Officers and Advisory Council Members, please visit the Division Website at http://www.sla.org/division/dpht/Members%20Only/of03.cfm, and for the first time in a while now we have almost every single position filled, so thank-you again to everyone who volunteered to take on a leadership role this year.

But of course, the 2003 Annual Meeting is over, so we are already working hard on planning events for the upcoming year. Karen Mirabile has been busy looking at hotels in Philadelphia – the chosen location for next year’s Spring meeting; Maude Lethiecq-Normand is working on completing proposals for not just one, but two Division-sponsored CE courses to be offered in Nashville and Damian Hayden is working hard to secure speakers for next year’s Annual Meeting (more details of which will appear in the next issue of CapLits).

So until then, keep in touch with one another; make use of the listserv to get some assistance in answering those tricky little questions, feel free to email me or any of the Board Members with suggestions for improving the way we do things.

And, as contracts and subscriptions come up for renewal, give those vendors hell – but once you have a price you’re happy with, don’t forget to thank them for their generous support of our Division!

Stephanie
Maximize Your Library Budget Dollars Without Sacrificing Content

An Affordable Annual Reviews Site License, Including Titles From the Annual Reviews Biomedical Suite, Can Help You Maximize Your Library Budget Dollars and STILL Deliver Exceptional Research Materials to Your Patrons

**Site License Features and Benefits Include:**

- One Site License - One Price - One Invoice
- Online-Only or Print+Online Option
- Single-Site, Multi-Site, and Consortia Licenses
- Custom Site License Solutions That Meet Your Needs. Choose all 19 Biomedical Titles or Create a Unique Combination of Titles for Your Institution
- Seamless Online Access to Full Text Articles, PDFs, Bibliographies, Reviews in Advance (RIA) and Other Supplementary Material in the Current Volume as well as the Last 4 Years of Back Volumes as They Become Available
- Visit www.annualreviews.org for a Complete List of Titles

**NEW in 2003 - The Annual Reviews Electronic Back Volume Collection**

Over 70 Years of Annual Reviews Content - Online and Available TODAY

Enhance your current Annual Reviews subscriptions with a comprehensive, fully searchable, and supplemented electronic collection of all Annual Reviews volumes ever published with content dating back to the very first volume of the Annual Review of Biochemistry™ in 1932. Take your holdings one step further - bridge the content gap and provide access to the remaining back volumes in each Annual Reviews series to give your patrons access to ALL Annual Reviews Content online.

Contact the Annual Reviews Site License Department today for more information regarding Site License Opportunities for your institution as well as the Annual Reviews Electronic Back Volume Collection.

**ANNUAL REVIEWS**
Nonprofit Publisher of the Annual Review of...™ Series
To Reach the Annual Reviews Site License Department:
Call Toll Free (US/Canada): 800.523.8635 or Worldwide: 650.493.4400
Email: sitelicense@annualreviews.org
www.annualreviews.org/cl2
Update on P&HT Strategic Plan

The Division’s Strategic Plan was developed with input from the Division membership and focus groups. The Plan was approved by the P&HT Board Members and then presented to the division membership at the June 2002 Annual Business Meeting. A copy of the Plan is included with this newsletter and also at http://www.sla.org/division/dpht/stratplan.htm. As described on the P&HT web page, the purpose of the plan is to “provide the Division with a road map for the future and serve as a communication tool for our membership. It is also intended to help us focus on our highest priorities and most important tasks and to hopefully, help us eliminate low-value activities and processes. All Division activities and decisions from this point forward must support our Strategic Plan and to this end the P&HT Board will review the Plan at both the Spring and Annual meetings on an ongoing basis. “

This year, the Strategic Plan is being used to support an important task: updating the Division’s Procedures Manual. The Manual provides a blueprint for each officer, committee head and appointed position, and needs to be updated periodically to take into account changes in the structure and activities of the Division. Therefore, it was decided that the Manual should be revised to reflect the current position responsibilities and to take into account the objectives and tactics outlined in the Strategic Plan. Each person with a position covered by the Procedures Manual will be revising their position description. Our goal is to have the new Procedures Manual completed by the next Annual Meeting.

In addition, each officer, committee head and appointed position has been asked to help implement the Strategic Plan by developing an action plan for their position. The action plans, based on guidelines in the Strategic Plan, will help us to implement many of the improvements and new initiatives that were recommended by the Division members during the development of the Strategic Plan. You will be hearing more about these activities during the coming months.

Janet Muscarella, Strategic Planning Chair

2004 P&HT Spring Meeting


More details will be announced shortly; please contact Karen Mirabile (kmirabile@pharma.wkhealth.com) if you have any questions.

SLA P&HT Division Treasurer’s Report

as of May 31, 2003

Income June 1, 2002 – May 31, 2003

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>SLA Allotment (726 @ $10.00)</td>
<td>$7,260.00</td>
</tr>
<tr>
<td>Interest</td>
<td>635.75</td>
</tr>
<tr>
<td>Bulletin Advertising</td>
<td>1,665.00</td>
</tr>
<tr>
<td>Meeting Income</td>
<td>57,435.00</td>
</tr>
<tr>
<td><strong>Total Income</strong></td>
<td><strong>$66,995.75</strong></td>
</tr>
</tbody>
</table>

Expenses June 1, 2002 – May 31, 2003

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bank Charge</td>
<td>$ 12.00</td>
</tr>
<tr>
<td>Bulletin Expenses</td>
<td>5,548.16</td>
</tr>
<tr>
<td>Meeting Expenses</td>
<td>65,773.06</td>
</tr>
<tr>
<td>Postage &amp; Supplies</td>
<td>1,278.44</td>
</tr>
<tr>
<td>Membership Directory</td>
<td>1,525.36</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>1,825.00</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td><strong>$75,962.02</strong></td>
</tr>
</tbody>
</table>

Income Minus Expenses

**$75,962.02** - **$-8,966.27**

Cash Balance as of 5/31/03

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>P&amp;HT – Pooled Account</td>
<td>$2,276.99</td>
</tr>
<tr>
<td>P&amp;HT – Checking</td>
<td>2,391.81</td>
</tr>
<tr>
<td>P&amp;HT – Savings</td>
<td>66,232.80</td>
</tr>
<tr>
<td><strong>Total Cash and Bank Accounts</strong></td>
<td><strong>$70,901.60</strong></td>
</tr>
</tbody>
</table>

Welcome to new division members!

Beth Carlin
Beverly Betley
Tamara Case
Cary Cochrell
Jodi Couch
Nancy Dvorin
Janet Everitt
Lella Dal Ferro
Cecelia French
Judy Gledhill
Betsy Hageman
Susan Hofmann
Laurie Howren
Carol Jariaga
Laura Mathews
Kathleen Love Moore
Cindy Mundahl
Michael Luesbrink
David Osterbur
Carole Ottenheimer
Brooke Raymond
Barbara Ringk
Mathew Salt
Marion Severy
Nelly Silva
Jonathan Silver
Denise Sliker
Carolyn Sosnowski
JoAnne Sparks
David Veinot
Julia Warren
Kathleen Weinrich
Erica Wiseman
Elizabeth Woods
Distinguished Member Award
Barbara Boyajian

Barbara Boyajian of Johnson & Johnson Pharmaceutical Research & Development, L.L.C. was presented the Distinguished Member Award by the Pharmaceutical & Health Technology Division of the Special Libraries Association on June 8, 2003 in New York City. Barbara is a manager in J&J PRD’s Global Scientific & Business Intelligence department.

The Distinguished Member Award honors a Pharmaceutical & Health Technologies (P&HT) Division member for notable and enduring contributions and service to the Division and the profession. This award represents a cumulative evaluation of an individual’s career and emphasizes sustained Division leadership and activity of a commendable nature.

A member of the P&HT Division for over 20 years, Barbara served as its Business Manager for a decade and as Treasurer for two years. She is currently serving as PH&T’s Fundraising Chair and solicited vendor sponsorship for this year’s PH&T Spring Meeting held in Chicago. Until recently, she had been the Advertising Manager for CapLits, the Division’s newsletter. In addition, she has served as Director for the Princeton-Trenton (NJ) Chapter of Special Libraries Association.

Barbara headed the J&J Worldwide Information Professionals Group for two years and continues to take a leadership role in this J&J’s Council of Research Directors (CORD) subcommittee. With the steady addition of new companies to J&J’s pharmaceutical sector, she readily reaches out to the information professionals within these newly-acquired organizations to assist in their acclimation to Johnson & Johnson. Throughout her career, Barbara has been innovative in information content delivery to her customers, continually providing quality products and services.

A strong advocate for the library & information science profession, especially within the pharmaceutical industry, Barbara exemplifies the best of Johnson & Johnson and the profession. Barbara is well-respected by her coworkers and information customers at J&J and is highly regarded among PH&T information professionals for her knowledge, wisdom, and leadership.

Susan Gleckner  
Johnson & Johnson Consumer & Personal Products

Horizon (New Member) Award
Sandra Caddell

On June 10, 2003, during the Pharmaceutical & Health Technology Division’s (P&HT) Annual Meeting in New York City, it was announced that Sandra Caddell won the Horizon Award. Sandra is a Knowledge Manager in the Strategy, Performance & Knowledge Services department at AstraZeneca.

The Horizon Award (also known as the New Member Award) honors a P&HT Division member of five (5) years or fewer who has shown promise of becoming an outstanding member of the profession. This award represents an evaluation of an individual’s work and participation in professional and division activities. Particular attention is given to involvement and contributions to the PH&T Division.

With encouragement from her Astra colleagues Sandra joined SLA and the P&HT Division. In 2001 she started working on PH&T fundraising with Regina Maxwell. Since then she has worked tirelessly. For the last two years Sandra has been Co-Fundraising Chair. For the 2003 Spring Meeting (Chicago) and the 2003 Annual Meeting (New York City) she helped to raise over $44K for the PH&T division’s 2003 meetings and events. Details from the P&HT Treasurer are listed below.

Without this funding many of the SLA PH&T educational sessions and events at the spring and annual meetings would not have happened.

In addition to her notable fundraising skills, Sandra has shown strong conflict resolution, negotiating, and meeting/convention organizational skills. The positive wave of energy and ideas she brings to SLA P&HT board meetings is well received by all.

Sandra has done a wonderful job of balancing work, school, volunteer work and her home life. With three children at home she earned her Masters of Library Science from Drexel University, started working for Astra USA (now AstraZeneca), and found time to actively participate in SLA. Sandra has been married for 19 years and has three teenagers.

Please help me congratulate Sandra on the wonderful work she has done for the division!

Bernadette Ewen, Aventis Pasteur
Your resource for the Pharmaceutical and Health Technology Division of the Special Libraries Association is...

For more information or a free product demonstration, please call 1.800.3DIALOG or visit www.dialog.com
MONICA MCKENZIE (1942-2003)

IN MEMORIAM

“We celebrate the life of Monica McKenzie, born on November 18, 1942 in Kingston, Jamaica, West Indies. She came to the USA in 1980.

Monica was the wife of Delroy McKenzie. Surviving are children - Kurt, Marc & Troy. Monica dedicated her life to her church, family and friends. She worked at First Boston and the New York Public Library and spent the last 15 years as a librarian with Schering-Plough Corporation. Monica is remembered by her colleagues at SLA.”

SLA Pharmaceutical and Health Technology Division Travel Award 2003

Library or Information Science students and members of the Pharmaceutical and Health Technology Division (DPHT) are invited to apply for a travel award of $1,500 to attend the Special Libraries Association (SLA) Annual Conference in 2004. Up to three travel awards will be granted.

Financial support is available to a qualified candidate who successfully responds to our request for a project. This project must take the form of an online resource evaluation, the design and production of a web page, or an essay on a topic that reflects a current issue/trend impacting our industry. The winning projects will be announced in “CapLits”, our Division newsletter and on our Division website.

Student applicants must be provisionally accepted or matriculated in an ALA-accredited Graduate School of Library or Information Science by January 31, 2004 and a member of (SLA). DPHT member applicants must be a member of the Division in good standing. All applicants must write and submit an online resource evaluation or design and produce a web page (with two linked pages), or write an essay on a topic that reflects a current issue/trend in the pharmaceutical or health technology industry. The project submitted must be no longer than three pages.

For more details, including special instructions and the submission address, see the online award announcement at [www.sla.org/committee/sarc/index.html](http://www.sla.org/committee/sarc/index.html) (under the section scholarships/stipends/awards) (the current announcement should be posted by 9/1/03). Applications must be postmarked or emailed by February 29, 2004 and winners will be notified by April 1, 2004.

Not eligible to apply? If you know a student who may be interested in working as an information professional in the pharmaceutical and health technology industry (library and information science students with a science background may be especially interested), please share this information and encourage them to apply for the travel award. After all, we need to do more to encourage students in to our discipline and what better way?

Interested in attending the Annual Meeting but your company is short of travel money? Regular DPHT members interested in the travel award are encouraged to conceive and execute a similar project and submit it by the deadline of February 2004.

If you have questions, please contact Margaret Basket, DPHT Scholarship and Student Affairs Chair, by email at mbasket@umich.edu.
Feedback from the 2003 Spring Meeting in Chicago - and plans for next year

“Begin in Imitation, but End in Innovation”

Stephanie Fitch

So...you dutifully fill out the feedback form at the end of the Spring Conference – and then what? Well, rest assured, we do take all your comments very seriously. Every feedback form is reviewed in detail. Every numeric rating is noted and every comment is read and considered – then the summary details are passed on to the Board and to the incoming Chair-Elect and the significance of all this is discussed at length so that we, on the Board, work to make the next Spring Meeting even better than the last.

But it’s possible that many of you didn’t even know that this all happens so, in an effort to try and meet one of the key objectives of the Strategic Plan and to increase communication between the Board and the Members, I thought it might be useful to include here in Caplits, a summary of the feedback we gathered this year – and some of the plans that we have for next year’s meeting as a direct result of that feedback.

First the location. Chicago got rave reviews from many people and the fact that it was neither ‘East’ nor ‘West’ appealed to a lot of members who attended (but of course, we don’t know feelings of those who didn’t attend but we’re going to survey everyone on meeting location during this term of office and finally tie down a definite rotation schedule). In addition, the ‘down-town’ location was very well received. This was something that we actually planned on this year based on last years’ feedback when some people commented on the fact that, even though the hotel in Princeton was very good, they would have preferred to be ‘in the city’ so...we’re going to build on our success and next year the Spring meeting will be in a down-town location, in Philadelphia. (Tentative dates are April 25-27, 2004.)

Next the venue. The vast majority of people were very happy with the hotel itself and with the food and with their rooms but one or two did comment that the hotel was rather expensive – a fact that is a down-side of being in the heart of a city. Going forward, the reality is that we probably won’t have a cheaper location next year (and this year’s room rate was the same as last year) but being in the city means that there will be cheaper alternatives relatively close-by for those who might not be able to afford to stay in the conference hotel itself. And what about the buffet-style meals? Again, a lot of people really liked this year’s arrangement (especially the vendors!) but a few attendees did state that they would have preferred the sit-down lunches that we had in Princeton. So, what are we planning for next year? To be honest, that all depends on the venue that gets chosen and Karen Mirabile is currently working hard to tie that down. Ideally, we’d like to have a buffet again but this time in the exhibit hall (this actually was the plan this year but we had so many vendors wanting to exhibit that we had to move the food in to the lobby area (or turn the vendors away which we didn’t want to do) but with the addition of tables and chairs for people to sit down at.

So talking of the vendors – how did people rate the exhibit hall this year? And the answer is ‘very highly’. A lot of people commented on the fact that we had a great set of vendors this year, that the atmosphere was very relaxed (no ‘hard sell’) and that the close proximity of the exhibit hall to the speaker room, was a real plus.

All of this means that we’ll try and find somewhere where we can have a similar set-up in Philadelphia, with the only difference being that we’re going to try and find somewhere even bigger because although we did move the food out in to the lobby area this year, we still ended up turning vendors away simply because we had no more booths to offer them! And more good news? At the Annual Meeting in New York, many vendors were asking us then for the dates of the Spring Meeting next year – even some who have never sponsored before so here’s to an even bigger turn-out in 2004!

Now what about the meeting itself? Comments from last year that we tried to address this year were (i) requests for a ‘stronger’ keynote speaker and (ii) suggestions that we include more ‘case-studies’ on the agenda, and we really succeeded in both regards. Most people loved Jeffrey Cufaude and he really set the scene for the whole conference. Of course, now the gauntlet is on the ground and Karen and her team have to find an even better keynote speaker for next year, but they have some good ideas and I’m sure they’ll find someone wonderful.

As for the other speakers, almost all of them did present case studies and almost all of them received very high ratings from those of you who attended. Of course, I’m not going to share individual ratings and comments about particular speakers here but I will pass on the fact, that every speaker was informed of their ‘average’ rating for both presentation skills and content of their talk and of specific comments made about their session and you can be certain that they all took their individual feedback seriously also.

Next a catch-all that I’m just going to label ‘logistics’. Last year several people wanted copies of the slides in their binders – and this year they got them! So this year, folk wanted
Small groups of conference attendees commandeered a number of taxis to arrive at the Flat Top Grill where guests are required to do a little improvisation themselves. Diners created their own dishes by combining into bowls a wide selection of meats, pastas, vegetables, spices, and sauces which were then cooked by a grill master on a large flat surface. The narrow eatery was wall-to-wall with librarians, information professionals, and information vendors.

From there, The Second City was just a few blocks walk through the slushy remains of that day’s snowstorm. The theater was founded in Chicago (until a few years ago, the U.S. city with the second largest population; hence, “The Second City”) in 1959. The comedy troupe writes and performs its own material. The theater launched the careers of such comics as John Belushi, Mike Myers, Bill Murray, Gilda Radner, and offers nightly comedy shows, as well as a variety of other programs and even services to teach and improve corporate communications.

On the wall just outside the seating area of the theater was a small whiteboard showing the names and numbers of reservations for the evening:

- Smith 10
- Jones 6
- Ford 8
- Fitch 93

Clearly, the librarians had now taken over Second City also!

The theater was small and dark, with lots of freestanding wooden chairs and tiny cocktail tables interspersed throughout for the audience. The short stage was bare, with a few simple chairs and multiple doorways lining the backdrop.

Well, that’s about it. Obviously, I haven’t addressed every single comment here that was entered on a feedback form but the main ‘themes’ are covered above and if you submitted a comment or a suggestion that you’d like an individual response to, please don’t hesitate to contact me. I still have all of your forms safely tucked in my desk (and believe me, for someone who doesn’t keep anything, that means that they are super important) plus I have them typed up and saved on my PC so I can definitely refer back if you’d like me to, and at the risk of sounding trite, what you think and comment on, really does matter. This is your Division; we want you to get the most out of it.

★★★★★

Second City Event Proves Popular

The majority of P&HT members at the Spring Meeting attended the conference’s “social event” on Monday night, April 28, 2003 which was dinner at a neighborhood restaurant paired with a performance at the famed Second City theater, known for improvisation.

We were entertained by a troupe of six very energized actors. The show started off with a bang...literally. An overly cheery morning person proved too-much-to-take for her housemate and was promptly “shot.” At times the actors asked the audi...
Our four step collaborative approach to tailor
your bibliographic solution

Put our tools to work for you:
- Comprehensive and customised data capture
- Rapid processing time
- Duplicate free
- Standard record format and indexing across multiple databases
- Customised indexing
- Retrospective record retrieval
- Full-text links

Set the wheels in motion:

Consult
- Partnership and consultation with key members of your team to ensure all business requirements are agreed and documented.

Design
- EMSCOPES professionals translate your business requirements into a solution design.

Implement
- In line with agreed infrastructure and resources the solution design is implemented in the timescales agreed.

Manage
- Via dedicated account management, the solution will be reviewed to ensure return on investment, that productivity and performance measures are met, and that overall customer satisfaction is realised.

Building Tailored Drug Literature Databases

Contact us at emscopes@elsevier.com
www.elsevier.com/locate/emscopes
Overview of Pharmaceutical and Health Technology Division’s Sessions

SLA’s Pharmaceutical & Health Technology Division had a very exciting annual meeting in New York. We were extremely pleased with the overwhelming attendance at all of our sessions and networking functions.

The P&HT division held three very popular networking breakfasts. Our division members find these so useful because it gives them a chance to interact with their peers and meet new members. The breakfasts are also used as a vehicle for informing our members about the activities at the conference. We would like to thank our sponsors who helped make these possible.

Some highlights from the P&HT division sessions were:

- Attendance at each session was standing room only. We were very pleased that each session far exceeded our expectations for attendance, and in particular the e-Journal session that attracted over 250 attendees.

- The introduction of a Town Hall format for one of our sessions. This format gave the attendees a chance to pose piercing questions regarding e-Journals to publishers and aggregators.

- The introduction of a new topic “PharmacoEconomics” that was well received by our members. This was a lively talk from a Professor at the University of New York at Buffalo and from Aventis Pharmaceuticals

- Division participation in several co-sponsored sessions with the BIO and Chemical Divisions. Particularly well-received was the joint session on Proteomics and Genomics which was then followed up by a session on Drug Discovery.

- Our Annual Business Luncheon which attracted approximately 150 attendees and provided yet another opportunity for our members to get involved in our Division and to network with each other.

To find more information on the P&HT Division or to view the electronic files of the presentations made in NY, go to [http://www.sla.org/division/dpht](http://www.sla.org/division/dpht).

Session Reviews

Beyond Science Fiction: Medical Technology in the 21st Century

June 9, 2003, Presented by Cindy Meisner and Beth White

Moderated by Julie David and Sandy Spurlock

This presentation was chock-full of precisely targeted, extremely relevant information for anyone engaged in the challenging task of searching for information in medical technology. There was standing room only for this presentation and most attendees stayed until the end as the interest and energy continued high for the entire hour and a half.

The first part of the presentation set the stage by describing key advances in medical technology over hundreds of years from the perspectives of medical instrumentation, operating rooms, and tools available to the surgeon. An informative timeline of key advances during the 20th century provided an excellent synthesis and perspective.

As a point of reference for looking ahead, the early 21st century is described as a time when surgical robots are commonplace for many procedures, telesurgery provides universal access to surgical procedures and training, drug-coated stents are in wide use, the “camera on a pill” is no longer in the realm of science fiction, and artificial corneal transplants are a reality.

The near future is predicted to hold “see and treat” devices; more widespread and efficacious computerized self-care; personal drug profiles; instant sealing bandages; vaccine and drugs added to everyday foods; ultrasonic injections and blood draws; use of expert systems as surrogate doctors; the eradication of inherited diseases by gene therapy; and computerized vision implants.

By the year 2025 the prediction is that neural networks will simulate thought processes; operating rooms will be com-
plete information systems; biochips will be commonplace; organ transplants will be routine along with the availability of many artificial organs; genetic engineering will have opened possibilities to “improve the self”; there will be a six-fold increase in new drugs; and genetically engineered children will be born.

And by 2080 those of us still around will see an increased healing rate of 200% - 300%; all cancer cured; a normal life span of 100 years; bloodless, sterile, painless surgeries; and the seamless blending of devices, drugs and biological processes.

The medical device industry will obviously be a key player in making such predictions a reality. A rich summary of statistics on the device industry presented the following information: first, there are between 5750 and 6000 device companies in the US alone. 17 large companies dominate 65% of the market. Interestingly, 80% of device companies have 50 or fewer employees.

The medical device market is estimated at $140 billion worldwide. US device revenues in 2003 are $63.2 billion, estimated to be $74.5 billion by 2005. The US produces about 50% of the world’s devices, and consumes over 40%.

Japan is the second largest market worldwide, followed by Germany and France as the only major players in Europe. New market opportunities exist in Asia, South America and Eastern Europe.

The following “key trend-drivers” are identified as large scale issues expected to influence the evolution of medical devices over the next 10 years. These include scientific advances in computer-related technology and molecular medicine; treatment delivery modalities such as home/self care and reduced invasiveness; specific product types such as drug/device combinations and organ replacements; the changing US health care system; microtechnology and nanotechnology; pharmaceutical developments such as drugs as alternatives to devices; and advances in cancer therapy and neurology.

So what’s an information professional to do in supporting companies operating in the medical device industry? There are many information challenges in this industry, according to the speakers. It is a non-traditional industry that is poorly defined and has a short history. There is therefore a limited subject-specific literature and information professionals must gain expertise in several disciplines.

To make matters worse there is weak coverage of this area in the literature and inadequate indexing to aid in locating relevant materials. Due to non-standardization of terms and poor coverage it is difficult to identify competitors.

In addition, there are large gaps in the data that has been collected that is needed for decision-making. For example, body/organ/tissue measurements are lacking, and comparable international data has not been collected.

Several suggestions for information support are recommended. Important document types to monitor include patents, market reports, conference proceedings, analyst reports, venture capital reports, and association publications. Most information centers use a “just in time” approach in that their collections are limited in size and information is purchased as needed. Searchers are reminded to cover non-traditional subject areas such as toys, video games, sewing and office supplies, and science fiction. Publications should be monitored from the following geographical “hot spots”: Minnesota, Boston, Indiana, Israel, and Japan.

Another recommendation is to use full-text searching of analyst reports, market reports, patents, and SEC filings. The following controlled vocabulary codes are necessary to know and use: SIC codes, NAICS codes, IPC codes, US Patent Class, FDA MDR codes; HCPCS codes, and CPT/ICD codes.

Advice on subject headings for the two primary medical literature databases include using the MEDLINE headings of “surgical instruments”, “surgical equipment”, and the topical...
ACS Publications is pleased to announce Molecular Pharmaceutics, a new journal focusing on molecular mechanistic approaches to the development of bio-available drugs and delivery systems.

A scholarly publication beginning bi-monthly publication in print with the January/February 2004 issue, and available online later this year, Molecular Pharmaceutics will publish articles & communications concentrating on the integration of applications of the chemical and biological sciences to advance the development of new drugs and delivery systems.

Molecular Pharmaceutics will promote high quality research advancing the understanding of pharmaceutics at the molecular level while providing a forum for research among the fields of physical and pharmaceutical chemistry, biochemistry, molecular and cell biology, and materials science focused on drug delivery. With an emphasis on fundamental molecular concepts in chemistry and biology as applied to drug and drug delivery system activity, the journal will showcase emerging technologies used to advance the drug development process.

Scientific areas include: physical and pharmaceutical chemistry, biochemistry, molecular and cellular biology; and polymer and materials science as they relate to drugs and drug development.

Submit your research to Molecular Pharmaceutics via the ACS Paragon System at http://pubs.acs.org/mp

Editor:

Gordon L. Amidon,
the Charles R. Walgreen Jr.
Professor of Pharmacy and
Professor of Pharmaceutical Sciences
at the University of Michigan.

Associate Editors:

K.D. Lee
University of Michigan

Carston R. Wagner
University of Minnesota

Volume 1, 2004 • 6 issues
Institutional Print Subscription Rate (US): $1100 • Outside North America: $1,130
subheading “instrumentation (IS)”; and the EMBASE heading “Medical apparatus, equipment and supplies”.

See Sources/Bibliography on the DPHT website. (http://www.sla.org/division/dpht/Annual2003/phtsla03.htm)

In summary this was an exhaustive and very relevant presentation of the history, trends and information sources in the medical technology industry. The speakers can be reached at:

Cindy Meisner
Ethicon Endo-Surgery Inc., Info Resource Center
4545 Creek Rd
Cincinnati, OH 45223
513-337-3578
c meisner@eesus.inj.com

Beth White
Beth White Research & Consulting Service,
1614 Westmoreland Ave
Cincinnati, OH 45223
513-541-2476
bwresearch@fuse.net

Review by Sandy Spurlock

PharmacoEconomics: A Question of Quality

Monday, June 9, 2003 from 11:30 a.m. – 1:00 p.m. in the Royal/Plymouth Rooms at the Marriott

Sponsored by Adis International

Speakers: Dr. Joseph Paladino at the SUNY, Buffalo and Mr. Jean Paul Gagnon, Aventis Pharmaceuticals

Dr. Paladino is a PharmD and Clinical professor at the State University of New York at Buffalo in the School of Pharmacy and Pharmaceutical Sciences. He is also the Director of Clinical Outcomes and PharmacoEconomics at CPL Associates in Amherst, New York.

Dr Paladino started with a discussion of cost-containment in pharmacies. He also discussed the fact that sometimes pharmacies, both hospital and retail, are short-sighted in how costs are contained. For example, a way to cut costs is to restrict the formulary, or restrict usage, substitute generics or other therapeutic substitutions, thinking of these will result in greater cost savings to the pharmacy or to the HMO. These tactics will, in the short run, cut costs. But, if patient does not get well faster because the drug does not work, or if the patient is hospitalized because a drug was not available, the result is more money spent. It might not be seen at the drugstore/pharmacy end of the question, but further “down the road”. In addition, if a pharmacy staff’s salary is based on how well pharmacy costs are decreased, the budget will decrease….but the patient will not be serviced well. In essence, look at the whole picture; i.e., what are the real costs involved in treating a patient?

What Dr. Paladino suggested is using information from pharmaeconomicists, and read what is being written in the literature about formularies and other means of cost containment. Learn about “outcomes based economic analysis”. Do things like require that pharmacists go with doctors on patient rounds to assist in evaluating the patients' pharmaceutical needs. Getting a patient well quickly is the best way to save drug dollars and is what the patient wants, also. A number of papers were referenced in the presentation.

Please see the Powerpoint presentation on the Division website (http://www.sla.org/division/dpht/Annual2003/phtsla03.htm).

Perspective on Outcomes and Effectiveness by Jean Paul Gagnon

Dr. Gagnon started by asking the question: Is outcome and effectiveness research really of value to pharmaceutical manufacturers? He posed this question because large investments are currently being made in health outcomes research by the pharmaceutical industry. This all adds to the cost of bringing a drug to market.

First, definitions:

PharmacoEconomics (health outcomes research): Research which identifies, measures and compares the costs and consequences of products and services, examines the impact of alternative drug therapies and deals with inputs/outputs (that is, the costs and consequences of activities).

Patient Reported Outcomes (PROs): The patient’s report of a health condition and treatment, encompassing quality of life issues, functioning, well-being, satisfaction, discomfort and productivity.

How is this information being used? Is it worth it to capture it?

This health outcomes information is being used to make decisions about what research projects to pursue and how companies should allocate resources to support those projects. Plus, outcomes research is used to determine pricing and value in the marketplace and (as far as a granting agency is concerned) reimbursement and inclusion on limited formularies. In addition, outcomes research can discover comparative product advantages and can enhance a company’s image. Therefore, as far as a company is concerned, pharmacoEconomics can be viewed as an r & d tool, a pricing tool, a marketing tool and a management tool.

Drug pricing and valuation can be determined by cost comparisons in the countries in which the drug will be (or is) sold. What else is on the market? What is coming? Are there unmet needs? Can the cost of the untreated or poorly treated disease be estimated? PROs are included in the cost analysis, along with the pharmacoEconomics data to assemble a true picture of both disease cost and drug development costs.

This is still a work in progress, as there is little agreement on guidelines for this kind of research and modeling.

Pharmaceutical executives are still not sure how useful this
kind of information is and whether it is really worth the cost, yet 67% of those interviewed stated that patients use some economic information to make better informed healthcare decisions. Most executives interviewed thought that their own company’s research lagged behind their competitors, so there is no good idea as to what is really needed in this research.

Dr. Gagnon summed up his thoughts with this statistic: Drug Costs as a percentage of US healthcare cost have climbed from 6% in the 1980s to 10% in 2000 and to an estimated 12.8% for 2008. This kind of expenditure will require evaluative research: we will continue to need to compare products (and other therapies) for disease impact and cost. This research will demand methodologies and guidelines to make those comparisons easier. Decision makers will have to learn how to use this data to support or drop projects. Government granting agencies and patients will both want to see better ways to evaluate drugs, and other therapies. Important? Yes! Is it of value to pharmaceutical manufacturers? Absolutely! The manufacturers should have a hand in determining those guidelines, not letting the guidelines be determined for them. This should also support bringing new products to the market.

**Biopharmaceutical Networking Breakfast**

Wednesday, June 11, 2003

Finance and Management Roundtable Discussion: Return on Investment (ROI), Metrics and Content Pricing

**Bibliography of relevant articles/papers compiled by Kathy McCabe, Bayer Diagnostics**

**Return on Investment (ROI)**

Demonstrating Value and Return on Investment: The Ongoing Imperative.” Roger Strouse. *Information Outlook*, 7(3), March 2003: 15-19. [http://www.sla.org/content/memberonly/infoonline/March03/Strouse.cfm](http://www.sla.org/content/memberonly/infoonline/March03/Strouse.cfm)


Value as Calculation and Value as Contribution to the Organization.” Jan Sykes. *Information Outlook*, 7(3), March 2003: 10-13. [http://www.sla.org/content/memberonly/infoonline/March03/SykesFeature.cfm](http://www.sla.org/content/memberonly/infoonline/March03/SykesFeature.cfm)

Valuing the Balanced Library Scorecard. Joseph Matthews. *Information Outlook*, 7(3), March 2003: 27-31. *(This article was adapted from his recently published book* The Bottom Line: Determining and Communicating the Value of the Special Library*, Westport, CT: Libraries Unlimited, 2002.)* [http://www.sla.org/content/memberonly/infoonline/March03/Matthews.cfm](http://www.sla.org/content/memberonly/infoonline/March03/Matthews.cfm)

**Content Pricing**


High value online services without the high price” Mary Ellen Bates. *SCIP Online*, 1(29), April 2003. [http://www.imakene.ws/scip2/e_article000141419.cfm](http://www.imakene.ws/scip2/e_article000141419.cfm)

Oultsell’s Industry Trends, Size, and Players in the General Aggregators, Distributors & Services Information Market: Free Download, November 2002 [http://www.sla.org/content/memberservice/infostore/recindreps.cfm](http://www.sla.org/content/memberservice/infostore/recindreps.cfm)

**Genomics and Proteomics – General Session**

Wednesday, June 11, 2003

Donald Lindberg from the National Library of Medicine (NLM) started the session with a general overview of genomics and stated that the human genomics project has redefined medicine. He showed simulations of the visible human with labeling structures with physical attributes. This technology provides clinicians and residents valuable experience without putting patients at risk. He joked around saying librarians are wonderful people who contribute to society and that we need to find the library gene.

The main focus of his talk was the enhancements made to Medline. When Medline was opened up to the public, usage went from 7 million to 70 million. The majority of these users were not doctors or librarians as had been previously. Medline now has links to the Center of Disease Control (CDC), gene tests and toxic elements. National Center for Biotechnology Information’s (NCBI) Entrez contains protein structures and gene indexing. LocusLink contains gene linking. Many of these links are to full-text resources. Searching in Spanish is now an option. There are public policy issues involved with genetic testing including the right to have tests done and controlling third party usage. At present, there is no federal legislation. He cited the Genetic Information Non-discriminatory Act, noting cases of genetic discrimination, and the Council for Responsible Genetics ([http://www.genewatch.org](http://www.genewatch.org)).
The Patent Searcher’s Search Firm

Which of the following challenges does your search team face?

✓
- Under staffing
- Heavy search load or backlog
- Looming deadlines
- Staff on vacation or extended leave
- Resources diverted to one-time or ongoing projects
- Manual searching needed at outside locations
- Searches outside of your normal subject specialization
- Time-consuming patent watches
- Other

Help is only a phone call or email away. At TPR International our experts speak the same search language as you and are ready to help you bridge the gap between the resources you have available and the workload on your plate.
Two copies of Stuart Brown’s new book *Essentials of Medical Genomics* were raffled off. Stuart Brown, affiliated with New York University’s (NYU) School of Medicine, provided an in-depth overview of genomics (application of high throughput automated technologies to molecular biology) and proteomics (identifying all of the proteins in an organism). Copies of Dr. Brown’s slides are available on the website [http://www.genomicshelp.com](http://www.genomicshelp.com) under the section Seminars and Courses Genomics for Librarians.

The job of the biologist is changing. They now spend more time using computers and on experimental design and data analysis and less time doing tedious lab biochemistry. Biology is becoming a more quantitative science. Librarians understand the challenges of storing and searching large amounts of data. The librarian’s role now involves training “computer savvy” scientists. Jobs change. Computers change. Scientists (and librarians) need to be adaptable and flexible.

Raw genomic data is useless even to the biologist. Data mining and multi-dimensional visualization tools are now available. With NCBI’s Entrez [http://www.ncbi.nlm.nih.gov/Entrez](http://www.ncbi.nlm.nih.gov/Entrez), GenBank can be searched where genes are linked to journal articles. OMIM (Online Mendelian Inheritance in Man) relates diseases to genes. There is still a vast area of uncertainty. Even though the human genome project is done, we still do not know how many genes are in the human body.

A lively question and answer period followed both talks. Dr. Brown addressed the issues of patient privacy and medical insurance relating to medical informatics and bioinformatics (the use of information technology to collect, analyze and interpret biological data).

**Genomics and Proteomics, Part 2: Legal Licensing**

The title of Mr. Drozdoff’s session was Patent Protection for Proteomics and Drug Discovery – Protecting Innovation without Stifling Development. Vladimir Drozdoff, Esquire, an intellectual property rights attorney with Clifford Chance US LLP, discussed the requirements of patentability. One of the major dilemmas within the field of proteomics is that patent claims do not describe an actual final drug product but instead biological or chemical reagents/intermediates. The Hatch-Waxman Act “Safe Harbor” tries to balance patent holders’ and generic drug makers’ rights. Recent court decisions have interpreted the Hatch Waxman Act broadly allowing manufacturers to conduct necessary testing for approval of generics before patents expire on innovator drugs. These court decisions have affected the scope of biological tools and research methods patents. Specific court cases involving major pharmaceutical companies were cited.

Mr. Drozdoff went on to discuss issues such as how much of the drug development process does the Hatch Waxman “Safe Harbor” apply? (can include early drug development) and can a patentee maintain any rights to exclude others from the market after drug approval? He closed the session discussing hot button issues including why license a product if protection is granted by safe harbor? When does trial and error become proof of concept? and How many end products are needed to support a generic claim? Nevertheless, royalties, annual licenses, partnering and cross licensing are still very important avenues to pursue especially when weighing the potential alternative – very expensive litigation.

**Julie David**

Senior Research Librarian, Daiichi Pharmaceutical Corp.

**Pharmaceutical and Health Technology Dinner at Becco in New York City**

Wednesday, June 11, 2003

Fourteen PHT members enjoyed a wonderful Italian meal as their dine-out social event at SLA/NYC. The arrangements were made by Karen Erani (Pfizer), our Networking Events coordinator, and even though she was not able to stay, she picked an excellent restaurant: Becco, on “Restaurant Row” (355 West 46th St., right down the block from the Marriott). This restaurant is owned by Lidia Matticchio Bastianich, who stars in Lidia’s Italian American Kitchen and Lidia’s Italian Table, cooking shows on PBS. She also owns Felidia in New York City, and Lidia’s in Kansas City and Pittsburgh. Becco was opened in 1993, and it is a favorite spot to eat on the West Side, as evidenced by the fact that we had to wait for 15 minutes, even with reservations. However, the food definitely made up for the wait.

From the Becco website [www.beconyc.com](http://www.beconyc.com), “the name Becco is derived from the Italian verb, beccare, which means to peck, nibble or savor something in a discriminating way.” We “beccared” our way through what the waiters called “family style” dining – a prix fixe meal that began with antipasto and Caesar salad, followed by platters of the three daily pasta selections. Following the pasta were platters of steak, chicken, shrimp, and accompanying vegetables, and finally dessert trays with several sweet choices. All of this was washed down of course with several good bottles of red and white wines. Passing platters and wine bottles made the meal feel like we were at an Italian home.

The conversation was as lively as the food was tasty. Division officers Chair-Elect Karen Mirabile (Wolters Kluwer Health), Current Chair Stephanie Fitch (Millennium), and Secretary Liz Perry (Gilead) were joined by PHT members from Eli-Lilly, Genzyme, Amylin, and Wyeth, as well as Adis, CAS, and DIALOG, to name a few. As the evening wore on and spirits loosened, a movement sprang up to convince Karen Mirabile to move the PHT spring meeting to Las Vegas next year. Although it did not work, and we are still on for Philadelphia in April, Vegas might be in the years to come!

Good food and good company made for a night well remembered. Thanks to everyone for making this “non-pharma” person feel comfortable and welcome. I, for one am looking forward to an equally memorable event in Nashville!

**Rebecca Miller, PhD student**

School of Library & Information Management

Emporia State University, Kansas
What is MediRegs?

MediRegs is a leading provider of regulatory and compliance research and information tools for the health and life sciences industries. MediRegs’ customer roster includes more than 700 health care providers, including 25 leading food, drug, device law firms, and numerous Fortune 50 food, global pharma and device companies, and the agencies that do the regulating.

MediRegs is more than just a content company

MediRegs combines the latest in publishing tools with an ASP platform of more than 1,000,000 documents and 2,000 databases (with access to over 80,000 FOIA documents) covering areas such as product development and approval, marketing, fraud and abuse, reimbursement, privacy, safety, enforcement, inspection, the courts, and more. The documents are specially tagged and indexed, with thousands of links that allow you to navigate from document to document so you can “read the story.”

MediRegs Products Include

- The Pharmaceutical Regulation Library™
- The European Pharmaceutical Regulation Library™
- The Device Regulation Library™
- The Food Regulation Library™
- The European Device Regulation Library™
- The Regulation and Reimbursement Library™

MediRegs Enterprise™

This fully customizable content platform allows you to build a custom solution using any of MediRegs’ 2,000 databases and tailor it to the organization, job, department, or process. MediRegs Enterprise clients can also add their own documents and resources and embed the regulations.

MediLink™

Use our MediLink technology and your intranet to build links from your own policies, procedures, and data resources into MediRegs’ databases, grounding your internal efforts with the regulatory citations.

MediRegs provides the most comprehensive, accurate, and timely health-care compliance and regulatory information for the United States. MediRegs software is intuitive and flexible, offering customization and personalization tools that allow users to tailor the products to fit their precise professional needs. We offer full training programs and search support. MediRegs is dedicated to providing unsurpassed customer service and to working closely with customers to meet their information needs. We have millions of documents already but if we don’t have it and you need it, we will do our best to get it. Let MediRegs be your compliance solution.

For more information regarding MediRegs products

Please contact us at sales@mediregs.com or call (800)808-6800.
Take a No Risk, No Hassle, No Obligation FREE TRIAL — www.mediregs.com

MediRegs, Inc. 1999-2003 • 20 William Street • Suite 310 • Wellesley Hills, MA 02481 • 800-808-6800 • fax 617-369-2510 • www.mediregs.com
“Second City,” continued from page 10.

can family going through its daily paces, with the setting changed each time to reflect very different decades.

A hack psychic held the stage in another scene, “reading” the minds of a few audience members, and predicting their futures. The Second City cast followed its initial bows with some true improvisation to close the evening.

Many thanks to Timely Data Resources, Otsell, Inc., and Ovid for sponsoring this popular event, and to Stephanie Fitch for organizing it.

Susan Gleckner
Johnson & Johnson Consumer & Personal Products
Cambridge Healthtech Institute Presents...

New Reports that Evaluate the Latest Drug Discovery and Development Technologies—and How They Will Impact Your Business

Cambridge Healthtech Institute (CHI), a leading producer of life science conferences, publishes reports that provide the information needed to translate the latest advancements in drug discovery and preclinical drug development into successful business strategies.

CHI Reports offer:
- Key scientific background.
- Evaluation of the leading companies and their approaches.
- Profiles of selected companies.
- Extensive commentaries from leading experts in the field.
- Business and strategic outlook.
- Analysis of recent business deals.

NEW RELEASES

Advances in Lead Optimization Accelerating Drug Discovery and Development

Life Sciences Informatics: From Data to Drugs

GPCRs: Mining the Richest Vein in Drug Discovery

Kinases: From Targets to Therapeutics

Cancer Genomics: Revolutionizing Treatment and Reshaping Markets throughTargeted Therapies

PUBLISHING SOON

Target Validation: Optimizing Target Selection in the Post-Genomic Era

Molecular Diagnostics: Emerging Applications Fuel Personalized Medicine

For more information about any report, including a table of contents and list of expert contributors, visit www.chireports.com.

Or contact: Cindy Ohlman, Phone: 617-630-1334, or E-mail: cohlman@healthtech.com

Cambridge Healthtech Institute, 1037 Chestnut Street, Newton Upper Falls, MA 024641
Report from the Medical Library Association (MLA) Meeting 2003

The Medical Library Association (MLA) met in San Diego May 1-8, 2003, with “Catch the Wave” as this year’s theme.

Programming featured the symposium “Evidence-Based Nursing Practice”, as well as the ever-growing Chapter Sharing Roundtable luncheon, with topics ranging from retirement planning to virtual reference. Open forums on scholarly publishing, compensation for medical librarians, and “hot topics” and “California chats” held poolside allowed great programming flexibility. In keeping with this year’s theme, one of the plenary sessions was entitled “Making waves: the untapped potential of medical libraries to improve the public’s health.” (Roz Diane Lasker, M.D.)

Attendees represented a range of library professionals, from new graduates to mid-, late-, and second-career, as well as solo, hospital, academic, government and corporate settings. The CE programs, plenary sessions, contributed papers and posters offered something for everyone, on topics including the following: cyberlaw, electronic resources, genomics, mentoring, public and consumer health, leadership, data mining, and collaborative strategies.

One of MLA’s newest Sections, Corporate Information Services, co-sponsored programs on virtual reference and information protection.

The symposium, general sessions and section programming were made available for the first time on CD instead of only audiotapes. The CD should soon be available via InterLibrary Loan from your area National Network of Libraries of Medicine (NN/LM).

Next year’s meeting will take place in Washington, D.C., with “Seize the Power” as the theme. Programming will include topics such as negotiation, advocacy, marketing and savvy and creative ways to use our valuable skills.

Mindy Paquette-Murphy, MLS
Senior Information Scientist
Sanofi-Synthelabo Research, Malvern, PA

Go ahead. Put us under the microscope.

We have pharmaceutical research translation down to a science.

Looking for a resource to translate foreign language research documents, case reports, protocols and more? Discover SH3. We specialize in translating pharmaceutical documentation. To learn more, visit www.sh3.com/pharma.
Tips from the DPHT Discussion List

Top pharma/biotech companies

Looking for a quick listing of the top pharmaceutical/biotech companies? I recently posted this question to the P&HT discussion list and was referred to some excellent sources.

Genetic Engineering News -- June issue -- Top 50 biotech/top 10 pharma

Med Ad News -- September issue -- Top 50 pharma companies (worldwide); and the current July issue has the top 100 biotech companies.

Pharmaceutical Executive -- May issue -- Top 50 pharma

Contract Pharma (online journal) -- July/August issue -- Top pharma and biopharma companies
http://www.contractpharma.com/current1.htm

Denise Armijo, maxim.com

Accessing the DPHT Website and Listserv

DPHT website:

http://www.sla.org/division/dpht

DPHT Listserv subscribing instructions:
1. Send your message to: LISTS@LISTS.SLA.ORG
2. Leave the subject line blank.
3. In the body of the message, type:
   SUBSCRIBE SLA-DPHT YOURFIRSTNAME YOURLASTNAME

DPHT Listserv sending instructions:
1. To post a message send it to:
   SLA-DPHT@LISTS.SLA.ORG
2. Put a meaningful subject in the subject line.
3. In the body of the message, type your message.
Navigate your way through combining databases.

BizInt Smart Charts  for Drug Pipelines

(formerly BizInt Smart Charts for Pharmaceuticals) will help you quickly create reports combining data from the leading drug pipeline databases.

Create tables in minutes and combine data from Pharmaprojects, R&D Focus, R&D Insight, IDdb and Prous. A new Generate Common Drug Name feature helps you quickly identify similar compounds from different databases.

Your report includes the table, images, and linked records. You can customize your report for different clients, view records and images, and distribute reports in several formats including HTML.

BizInt Solutions
650 North Costello Pl
Orange, CA 92869 USA
1.714.289.1000 TEL
1.714.744.1316 FAX
www.bizcharts.com

Visit our website
www.bizcharts.com
for a free trial!